Do You Believe in The Long-Term Growth Outlook of Thermo Fisher Scientific (TMO)?
Baron Capital's Baron Health Care Fund maintains a positive long-term outlook for Thermo Fisher Scientific (TMO) despite a recent stock decline due to pressures in the life sciences sector. The fund believes TMO's dominance across multiple markets and scale will lead to high-single-digit organic growth and double-digit earnings-per-share growth once macroeconomic conditions stabilize. TMO's Q1 2026 revenue increased by 6% year-over-year to $11.01 billion, and it remains a significant holding for hedge funds.
https://finance.yahoo.com/sectors/healthcare/articles/believe-long-term-growth-outlook-131250680.html